Detalhe da pesquisa
1.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
N Engl J Med
; 377(9): 839-848, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28854085
2.
Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.
Ann Intern Med
; 170(6): 423-426, 2019 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30508430
3.
Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events.
Cancer Rep (Hoboken)
; 6(1): e1627, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579862
4.
Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.
Diab Vasc Dis Res
; 15(5): 465-468, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29947247
5.
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.
Diabetes Care
; 41(10): 2229-2235, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30072400
6.
[ST-segment elevation myocardial infarction following treatment with sumatriptan]. / ST-elevations-myokardieinfarkt efter indtagelse af sumatriptan.
Ugeskr Laeger
; 167(1): 62-3, 2005 Jan 03.
Artigo
em Dinamarquês
| MEDLINE | ID: mdl-15675172